Open Label Extension Study With Gefitinib (IRESSA™) for Completing Trial Patients Who May Benefit From Further Treatment
NCT00683306
·
clinicaltrials.gov ↗
APPROVED_FOR_MARKETING
Status
INDUSTRY
Sponsor class
Conditions
Non Small Cell Lung Cancer (NSCLC)
Interventions
DRUG:
ZD1839 (Iressa)
Sponsor
AstraZeneca